Eli Lilly Acquires Engage Bio to Accelerate Development of Non-Viral Genetic Medicines

Eli Lilly and Company has acquired Engage Bio in a strategic move aimed at advancing next-generation non-viral genetic medicines and expanding Lilly’s growing presence in genetic medicine innovation.

According to the announcement, the acquisition will combine Engage Bio’s proprietary DNA delivery platform with Lilly’s global research, development, and commercialization capabilities to accelerate the development of innovative therapeutic approaches.

Engage Bio has spent the last several years developing technologies designed to overcome one of the most significant challenges in genetic medicine: delivering therapeutic DNA without relying on viral vectors. The company’s platform focuses on improving tolerability, expression, redosability, and scalability while reducing many of the limitations associated with traditional viral delivery systems.

The company noted that the complexity of non-viral DNA delivery stems from the human cell’s evolved defense mechanisms, including nuclear barriers and innate immune sensors that actively prevent foreign DNA uptake. Engage Bio’s platform was specifically engineered to address these challenges through a non-viral delivery approach aimed at enabling safer and more repeatable therapeutic applications.

The acquisition reflects Lilly’s continued investment in advanced biotechnology platforms and emerging therapeutic modalities. Over the past several years, the company has steadily expanded its genetic medicine and cell therapy capabilities through acquisitions and partnerships across the biotechnology ecosystem.

Leadership at Engage Bio described Lilly as a partner willing to make early and decisive investments in transformative technologies, emphasizing the potential for the combined organizations to accelerate the future development of DNA medicines.

The transaction also highlights the broader pharmaceutical industry trend toward next-generation gene delivery systems that move beyond conventional viral-vector approaches. As genetic medicine advances, scalability, repeat dosing, safety, and manufacturing simplicity are becoming increasingly important priorities for biotech and pharmaceutical companies alike.

About Eli Lilly and Company:

Eli Lilly and Company is a global pharmaceutical company focused on developing medicines across oncology, immunology, neuroscience, cardiometabolic disease, and genetic medicine. The company continues to expand investments in biotechnology innovation, AI-driven drug discovery, and advanced therapeutic platforms.

About Engage Bio:

Engage Bio is a biotechnology company developing non-viral DNA delivery technologies for genetic medicine applications. Its platform is designed to improve potency, tolerability, and repeat dosing capabilities while addressing limitations associated with traditional viral-vector delivery systems.